AbbVie Collaborates with Global Health Authorities to Investigate its Kaletra/Aluvia (lopinavir/ritonavir) Against COVID-19

 AbbVie Collaborates with Global Health Authorities to Investigate its Kaletra/Aluvia (lopinavir/ritonavir) Against COVID-19

AbbVie Collaborates with Global Health Authorities to Investigate its Kaletra/Aluvia (lopinavir/ritonavir) Against COVID-19

Shots:

  • AbbVie collaborates with global health authorities, including the FDA, CDC, BARDA, NIH, EU health authorities and Chinese officials to determine the safety & efficacy of Kaletra/Aluvia against COVID-19
  • AbbVie donated Aluvia to the Chinese government for experimental use against COVID-19 and has joined the Innovative Medicines Initiative to support research and discovery of therapies against COVID-19
  • AbbVie is actively evaluating the increased demand for Kaletra/Aluvia and has taken steps to improve supply for COVID-19 patients without impacting treatment supply for HIV patients

Click here ­to­ read full press release/ article | Ref: AbbVie | Image: Telegram

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post